泰山石化(01192.HK)補回公布附屬曾斥940萬人幣向關連方購綜合服務業務權益
泰山石化(01192.HK)公布,間接全資附屬泰山企業管理諮詢曾於2017年12月28日與張謙東訂立股權轉讓協議,對方以總代價940萬元人民幣將上海耀炫之全部股本轉讓予泰山企業管理諮詢。
張謙東在相關時刻為上海耀炫之唯一股東,以及公司之主要股東華匯資本的最終實益擁有人。
上海耀炫於合資公司持有的20%股權,合資公司打算依託中國上海市虹口區北外灘的政策及區位優勢,提供船舶修理、船舶建造、船舶改裝、海工建設及海事服務的綜合服務業務。
根據上市規則第14A章,延遲刊發公告構成公司的不合規行為。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.